Assessment of safety and efficacy of triple regimen in Acute on chronic liver failure ( ACLF ) patients with large ascites and acute kidney injury with slow albumin ,furosemide and vasoconstrictors therapy versus albumin and vasoconstrictors and oral dirutics
- Conditions
- Health Condition 1: K746- Other and unspecified cirrhosis ofliverHealth Condition 2: K746- Other and unspecified cirrhosis ofliver
- Registration Number
- CTRI/2020/04/024521
- Lead Sponsor
- Institutional Ethics Committee Sanjay Gandhi Institute of Medical Sciences Lucknow
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
b.ACLF as per EASL- CLIF definition, 2013
c.AKI-HRS as per ICA 2007 definition (reduction in renal function was defined as SCr >=226 lmol/L and/or a doubling of SCr within 2 weeks with patients have no sustained improvement in renal function during the pre-enrolment screening). All patients will undergo fluid challenge with intravenous albumin to demonstrate that volume expansion was insufficient to correct renal failure, and specific inclusion criteria will be applied for the SCr response 48 h after diuretic withdrawal and albumin administration ( <20% decrease in SCr and SCr >=199 lmol/L)
a.CKD G5; eGFR <30 ml/min.
b.Patient with AKI-HRS who has already underwent hemodialysis before enrollment
c.Severe cardiopulmonary disease, terminal cancer
d.Patient with HCC on screening ultrasound
e.Patient with portal/superior mesentric vein thrombosis on screening ultrasound
f.Ongoing shock or uncontrolled bacterial infection.
g.Patients receiving octreotide, midodrine, vasopressin, dopamine or other vasopressors within 48 h, as well as
h.patients who received <2 days of anti-infective therapy for suspected or documented infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method